All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ATH-1017
Therapeutic Area: Neurology Product Name: ATH-1017
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 01, 2020
Details:
The Phase 2/3 clinical trial is a randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of ATH-1017 in individuals with mild-to-moderate Alzheimer’s disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Atuzaginstat
Therapeutic Area: Neurology Product Name: COR388
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2020
Details:
GAIN Trial for Alzheimer’s disease (AD) has exceeded its enrollment target of 570 patients. GAIN is a randomized, double-blind, placebo-controlled Phase 2/3 trial of atuzaginstat (COR388), Cortexyme’s lead investigational medicine, in patients with mild to moderate AD.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Zavegepant
Therapeutic Area: Neurology Product Name: BHV-3500
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2020
Details:
Zavegepant is a third generation, high affinity, selective and structurally unique, small molecule CGRP receptor antagonist in development for both migraine and non-migraine indications including COVID-19 associated lung inflammation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Blarcamesine
Therapeutic Area: Neurology Product Name: Anavex 2-73
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2020
Details:
The multi-center, double-blind clinical study at 8 sites across U.S. measured safety, tolerability, and efficacy of daily oral ANAVEX®2-73 (blarcamesine) doses or placebo.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CNM-Au8
Therapeutic Area: Neurology Product Name: CNM-Au8
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2020
Details:
The multi-center study is designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in early symptomatic ALS patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tauroursodeoxycholic Acid,Sodium 4-Phenylbutyrate
Therapeutic Area: Neurology Product Name: AMX0035
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2020
Details:
Patients retained function longer on AMX0035 versus placebo; study achieved its primary outcome of a difference on the revised als functional rating scale.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Atuzaginstat
Therapeutic Area: Neurology Product Name: COR388
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2020
Details:
Cortexyme's ‘826 patent provides additional composition of matter protection for atuzaginstat and gingipain inhibitors, with additional claims pending in related applications.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CNM-Au8
Therapeutic Area: Neurology Product Name: CNM-Au8
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: SymBiosis II, LLC
Deal Size: $42.5 million Upfront Cash: Undisclosed
Deal Type: Series D Financing August 26, 2020
Details:
Funds will be used to advance Clene’s clinical pipeline through its ongoing Phase 3 study for the treatment of ALS, and multiple Phase 2 clinical trials for the treatment of progressive neurologic impairment seen in people suffering from M.S, Parkinson’s disease, and ALS.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Atuzaginstat
Therapeutic Area: Neurology Product Name: COR388
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 14, 2020
Details:
GAIN is a randomized, double-blind, placebo-controlled Phase 2/3 trial of atuzaginstat (COR388), Cortexyme’s lead investigational medicine, in patients with mild to moderate AD.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Zavegepant
Therapeutic Area: Neurology Product Name: BHV-3500
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Royalty Pharma
Deal Size: $450.0 million Upfront Cash: Undisclosed
Deal Type: Funding August 07, 2020
Details:
Funding will advance the Biohaven's CGRP receptor antagonist program through the development of zavegepant (vazegepant). The zavegepant program encompasses intranasal zavegepant as well as oral zavegepant for migraine prevention and non-migraine indications.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
